November 08, 2017
Arena Pharmaceuticals Inc. has reached a $24 million cash-and-stock deal with a proposed class of investors to settle its seven-year battle in California federal court over allegations the company lied to shareholders that testing was going smoothly for its diet drug lorcaserin, which is sold under the trade name Belviq.
January 10, 2017
The Ninth Circuit on Tuesday denied Arena Pharmaceuticals' request for a full panel rehearing of its decision that revived a proposed class action alleging the company lied to shareholders that testing for its new diet drug was going smoothly.